TP53 and acute myeloid leukemia: A groundbreaking clinical case demonstrated the first successful use of CD7 CAR-T cell therapy in a patient with relapsed/refractory acute myeloid leukemia (r/r AML) carrying high-risk mutations, including TP53 deletion, FLT3-ITD, and SKAP2-RUNX1 fusion (NCT04762485).